All In Biotech

Drug Trial Radar · NCT03936777

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Apr 22, 2019

Primary completion

May 8, 2025

Study completion May 8, 2025

Sponsor

Lead sponsor
Zogenix, Inc.Industry
Sponsor type
Industry
Collaborators
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
First posted
May 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy

Conditions

  • Dravet Syndrome
  • Lennox Gastaut Syndrome
  • Epileptic Encephalopathy

Interventions

  • ZX008 (Fenfluramine Hydrochloride)Drug

    Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days)

Locations

71 sites in 14 countries. Site status is shown where the registry gives one.

  • Ep0215 107

    Tucson, Arizona

  • Ep0215 144

    Los Angeles, California

  • Ep0215 108

    San Diego, California

  • Ep0215 101

    San Francisco, California

  • Ep0215 103

    Aurora, Colorado

  • Ep0215 115

    Gulf Breeze, Florida

  • Ep0215 104

    Miami, Florida

  • Ep0215 141

    Orlando, Florida

  • Ep0215 121

    Winter Park, Florida

  • Ep0215 117

    Atlanta, Georgia

  • Ep0215 110

    Chicago, Illinois

  • Ep0215 140

    Bethesda, Maryland

  • Ep0215 112

    Boston, Massachusetts

  • Ep0215 109

    Rochester, Minnesota

  • Ep0215 132

    Roseville, Minnesota

  • Ep0215 105

    Hackensack, New Jersey

  • Ep0215 118

    Livingston, New Jersey

  • Ep0215 150

    Hawthorne, New York

  • Ep0215 142

    New York, New York

  • Ep0215 131

    Cleveland, Ohio

  • Ep0215 124

    Memphis, Tennessee

  • Ep0215 146

    Dallas, Texas

  • Ep0215 126

    Fort Worth, Texas

  • Ep0215 106

    Salt Lake City, Utah

  • Ep0215 119

    Seattle, Washington

  • Ep0215 125

    Tacoma, Washington

  • Ep0215 301

    Heidelberg, Australia

  • Ep0215 302

    South Brisbane, Australia

  • Ep0215 303

    Westmead, Australia

  • Ep0215 803

    Brussels, Belgium

  • Ep0215 801

    Edegem, Belgium

  • Ep0215 802

    Jette, Belgium

  • Ep0215 202

    Montreal, Canada

  • Ep0215 204

    Toronto, Canada

  • Ep0215 201

    Vancouver, Canada

  • Ep0215 701

    Dianalund, Denmark

  • Ep0215 1004

    Bordeaux, France

  • Ep0215 1005

    Lille, France

  • Ep0215 1007

    Marseille, France

  • Ep0215 1001

    Paris, France

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.